Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical, Inc. \De\ (LFCR) Invested Capital (2016 - 2025)

Historic Invested Capital for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $131.8 million.

  • Lifecore Biomedical, Inc. \De\'s Invested Capital fell 309.67% to $131.8 million in Q2 2025 from the same period last year, while for May 2025 it was $131.8 million, marking a year-over-year decrease of 309.67%. This contributed to the annual value of $131.8 million for FY2025, which is 309.67% down from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its Invested Capital stood at $131.8 million for Q2 2025, which was down 309.67% from $127.2 million recorded in Q1 2025.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Invested Capital peaked at $366.8 million during Q2 2021, and registered a low of $75.3 million during Q3 2023.
  • In the last 5 years, Lifecore Biomedical, Inc. \De\'s Invested Capital had a median value of $135.0 million in 2023 and averaged $177.1 million.
  • As far as peak fluctuations go, Lifecore Biomedical, Inc. \De\'s Invested Capital plummeted by 5734.06% in 2023, and later surged by 6870.08% in 2024.
  • Lifecore Biomedical, Inc. \De\'s Invested Capital (Quarter) stood at $279.6 million in 2021, then crashed by 39.17% to $170.1 million in 2022, then plummeted by 44.57% to $94.3 million in 2023, then soared by 34.44% to $126.8 million in 2024, then rose by 3.96% to $131.8 million in 2025.
  • Its last three reported values are $131.8 million in Q2 2025, $127.2 million for Q1 2025, and $126.8 million during Q4 2024.